Amicus Therapeutics to Present at Upcoming Investor Conferences
Amicus Therapeutics (Nasdaq: FOLD), a dedicated player in the biotechnology landscape, has announced its forthcoming participation in significant investor conferences this September, showcasing its unwavering commitment to fostering investor relations.
Details of the Upcoming Presentations
The company has structured its schedule around two important events. The first is the Cantor Global Healthcare Conference, taking place in New York on September 3. Amicus’s management is set to present at 10:20 a.m. ET. This event is vital for connecting with other innovators and investors in the healthcare sector.
Shortly after, on September 9, the Morgan Stanley 23rd Annual Global Healthcare Conference will follow, with a presentation scheduled for 3:20 p.m. ET. Both events present ripe opportunities for Amicus to share its vision and progress in treating rare diseases, an area where the company has made significant advancements.
Accessing the Live Webcasts
For those unable to attend the conferences, there is an avenue to catch the presentations live. Audio webcasts will be accessible through the investors section of Amicus Therapeutics’ corporate website. This initiative is a part of the company's strategy to maintain transparency and keep its stakeholders informed about its pioneering efforts in biotechnology.
About Amicus Therapeutics
Amicus Therapeutics stands out in the biotechnology environment, focusing on the discovery and development of innovative therapies for rare diseases. With a patient-centric philosophy, the company is dedicated to delivering high-quality treatments that offer hope to patients with unmet medical needs.
The company’s research pipeline is robust, with a range of emerging therapies designed to be either groundbreaking or significantly improve upon existing options. Their commitment to excellence is evident as they continue to push the boundaries of medical science, striving to provide effective solutions for patients who need it the most.
Contact Information for Investors and Media
For investors looking for more information, Amicus has made available contact details for key personnel. Andrew Faughnan, Vice President of Investor Relations, can be reached at (609) 662-3809 or via email. Diana Moore, Vice President of Corporate Communications, is another contact for media inquiries, similarly available through email and phone.
Frequently Asked Questions
What is the focus of Amicus Therapeutics?
Amicus Therapeutics concentrates on developing high-quality therapies for individuals with rare diseases.
Where can I access the live presentations?
The live audio webcasts of the presentations will be accessible through the investors section of Amicus Therapeutics’ website.
What are the dates of the upcoming conferences?
Amicus will be presenting at the Cantor Global Healthcare Conference on September 3 and at the Morgan Stanley Annual Global Healthcare Conference on September 9.
How can I contact the investor relations at Amicus Therapeutics?
Investors can contact Andrew Faughnan, Vice President of Investor Relations, at (609) 662-3809.
What is the significance of these investor conferences?
These conferences are crucial for Amicus Therapeutics to engage with investors, provide updates on its innovations, and foster strong relationships in the biotechnology sector.
